JAMA cardiology最新文献

{"title":"Evidence About Benefits and Risks of Vaccines: Challenges in Science, Medicine, Public Health, and Culture.","authors":"Robert M Califf","doi":"10.1001/jamacardio.2025.3521","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.3521","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":" ","pages":""},"PeriodicalIF":14.1,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systolic Blood Pressure and Microaxial Flow Pump-Associated Survival in Infarct-Related Cardiogenic Shock: A Post Hoc Analysis of the DanGer Shock Randomized Clinical Trial.","authors":"Astrid Duus Mikkelsen, Rasmus Paulin Beske, Lisette Okkels Jensen, Hans Eiskjær, Norman Mangner, Amin Polzin, Christian Schulze, Carsten Skurk, Peter Nordbeck, Benedikt Schrage, Vasileios Panoulas, Sebastian Zimmer, Andreas Schäfer, Thomas Engstrøm, Lene Holmvang, Martin Frydland, Anders Bo Junker, Henrik Schmidt, Nanna Louise Junker Udesen, Kristian Wachtell, Christian Juhl Terkelsen, Axel Linke, Jesper Kjærgaard, Jacob Eifer Møller, Christian Hassager","doi":"10.1001/jamacardio.2025.3337","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.3337","url":null,"abstract":"<p><strong>Importance: </strong>Microaxial flow pump treatment improves survival in selected patients with infarct-related cardiogenic shock; however, treatment carries substantial risks, and benefit may vary by patient subgroup. Systolic blood pressure (SBP) has been proposed as a modifier of the survival benefit.</p><p><strong>Objective: </strong>To investigate whether SBP at randomization modifies the survival benefit of microaxial flow pump treatment in ST-segment elevation myocardial infarction-related cardiogenic shock.</p><p><strong>Design, setting, and participants: </strong>This was a post hoc analysis of the Danish-German (DanGer) Shock open-label randomized clinical trial among adult patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock, conducted between 2013 and 2023 at 14 tertiary invasive cardiac centers in Denmark, Germany, and the United Kingdom. Data analysis was performed from January 7 to April 7, 2024.</p><p><strong>Intervention: </strong>Microaxial flow pump therapy plus standard care vs standard care alone.</p><p><strong>Main outcomes and measures: </strong>All-cause mortality at 180 days according to randomization SBP.</p><p><strong>Results: </strong>Of 355 patients included in the DanGer Shock trial, 351 patients had available SBP at randomization (median [IQR] age, 69 [59-76] years; 277 [79%] male). In a dichotomized regression analysis, microaxial flow pump treatment significantly reduced mortality for SBPs lower than 82 mm Hg compared with standard care alone (odds ratio [OR], 0.34; 95% CI, 0.18-0.63; P < .001). This was not evident for higher pressures (OR, 0.96; 95% CI, 0.53-1.70; P = .90; P for interaction = .02). Kaplan-Meier survival analysis and spline regression analysis supported these findings (P for interaction = .02; P for nonlinearity = .01).</p><p><strong>Conclusions and relevance: </strong>Randomization SBP was associated with the survival benefit of microaxial flow pump treatment, with the most hypotensive patients deriving the largest survival benefit. Early SBP may help identify patients most likely to gain a net benefit from microaxial flow pump treatment. Findings are hypothesis generating.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT01633502.</p>","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":" ","pages":""},"PeriodicalIF":14.1,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12398770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Outcomes With Personalized Accelerated Physiologic Pacing in Heart Failure With Preserved Ejection Fraction","authors":"Margaret Infeld, Jamie Cyr, Alexandra E. Novelli, Rebecca Rawlings, Kramer Wahlberg, Timothy B. Plante, Jeanne du Fay de Lavallaz, Nicole Habel, Daniel L. Lustgarten, Markus Meyer","doi":"10.1001/jamacardio.2025.2827","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2827","url":null,"abstract":"ImportancePatients with heart failure with preserved ejection fraction (HFpEF) and physiologic pacemakers may benefit from pacing rates above the standard 60 beats per minute (bpm).ObjectiveTo compare adverse event accrual between personalized accelerated pacing and usual care in HFpEF.Design, Setting, and ParticipantsThis was an observational extension of the myPACE randomized clinical trial with up to 4 years of follow-up in 100 patients with stage B or C HFpEF and preexisting physiologic pacemakers treated at the University of Vermont Medical Center. The myPACE study was conducted from June 2019 to December 2021; follow-up for this report was concluded in June 2023.InterventionParticipants in the original myPACE trial were randomly assigned to either personalized accelerated pacing (myPACE) or 60 bpm (usual care).Main Outcomes and MeasuresThe primary outcome was the accrual of first and recurrent adverse clinical events during the open-label follow-up phase—including urgent visits or hospitalizations for heart failure or atrial fibrillation, myocardial infarction, stroke, or death—assessed using an intention-to-treat (ITT) analysis and a prespecified per-protocol (PP) analysis of patients who continued their assigned treatment. Secondary outcomes included event-free survival in both ITT and PP analyses.ResultsAmong the 100 original trial participants (48 in myPACE and 52 in usual care), the ITT analysis demonstrated a trend toward slower event accrual with the myPACE intervention (15 vs 33 events; Lin-Wei-Ying-Yang estimate [LWYY], 0.48; 95% CI, 0.22-1.06; &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .07) and longer event-free survival (hazard ratio [HR], 0.63; 95% CI, 0.31-1.29; &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .20) but did not reach statistical significance. In the prespecified PP analysis, 87 remained on their assigned heart rate setting over the 4-year follow-up (39 in myPACE and 48 in usual care). The mean (SD) age was 74 (10) years, and 48 participants (55%) were male. In this PP analysis, myPACE was associated with a slower accrual of clinical events (5 vs 31 events; LWYY, 0.16; 95% CI, 0.04-0.67; &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .01) and longer event-free survival (HR, 0.30; 95% CI, 0.11-0.80; &lt;jats:italic&gt;P&lt;/jats:italic&gt; = .02) compared to usual care. These results were primarily driven by heart failure–related events.Conclusions and RelevanceIn this observational clinical events analysis of the myPACE trial, analysis by ITT did not achieve statistical significance between study arms. However, PP analysis showed that personalized accelerated physiologic pacing was associated with a slower accrual of adverse clinical events compared with the standard 60-bpm setting. These results are hypothesis generating and warrant confirmation in larger multicenter trials.Trial RegistrationClinicalTrials.gov Identifier: &lt;jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://clinicaltrials.gov/study/NCT04721314\"&gt;NCT04721314&lt;/","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"9 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival After Initial Stress Testing vs Anatomic Testing in Suspected Coronary Artery Disease","authors":"Pamela S. Douglas, Amanda Stebbins, Borek Foldyna, Manesh R. Patel, Daniel B. Mark, Michael T. Lu, Udo Hoffmann, Svati H. Shah, Beth Martinez, Brooke Alhanti, Neha Pagidipati","doi":"10.1001/jamacardio.2025.2882","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2882","url":null,"abstract":"ImportanceSymptoms suggestive of coronary artery disease (CAD) often require noninvasive testing for diagnostic and prognostic evaluation.ObjectiveTo determine long-term outcomes in patients randomized to functional (stress) vs anatomic (coronary computed tomographic angiography [CTA]) initial testing.Design, Setting, and ParticipantsThis study is a 2025 follow-up analysis of mortality of participants in the PROMISE (Prospective Multicenter Imaging Study for Evaluation of Chest Pain) randomized clinical trial, which was conducted from 2009 to 2014, using a 2024 National Death Index search. Median (IQR) follow-up duration was 10.6 (9.9-11.3) years; maximum follow-up was 12.4 years. PROMISE was conducted at 193 multispecialty outpatient sites in North America among 10 003 symptomatic patients requiring testing for suspected CAD. Data analysis was conducted from August 2024 to March 2025.InterventionParticipants were randomized 1:1 to initial CTA or stress testing. Testing and subsequent care were performed by sites according to usual practices.Main Outcomes and MeasuresThe PROMISE trial’s original primary end point was death, myocardial infarction, unstable angina hospitalization, or major procedural complication. The primary end point for extended follow-up was all-cause death, with cardiovascular (CV) death as a secondary end point.ResultsAt enrollment, mean (SD) participant age was 61 (8) years, 5270 participants (52.7%) were women, and 8762 (87.6%) had chest pain or dyspnea. Death occurred in 1128 participants (14.4%), including 558 (14.3%) in the CTA arm and 570 (14.5%) in the stress arm (unadjusted hazard ratio [HR], 0.98; 95% CI, 0.87-1.10). There was no demonstrable difference in cardiovascular mortality, although the point estimate favored CTA (HR, 0.84; 95% CI, 0.67-1.05; adjusted HR, 0.89; 95% CI, 0.41-1.94). There were no significant interactions between all-cause death or CV death and study arm by age (&amp;amp;lt;60 or ≥60 years) (&lt;jats:italic&gt;P&lt;/jats:italic&gt; value for interaction = .19), gender (&lt;jats:italic&gt;P&lt;/jats:italic&gt; value for interaction = .60), or race and ethnicity (&lt;jats:italic&gt;P&lt;/jats:italic&gt; value for interaction = .47). A CTA indicating any degree of abnormality, including mild (nonobstructive CAD), moderate, and severe findings, conferred elevated adjusted HRs of death (1.99-3.44; all &lt;jats:italic&gt;P&lt;/jats:italic&gt; &amp;amp;lt; .001) compared to normal study results. Among stress testing results, only a severe abnormality was prognostically significant (HR, 1.45; 95% CI, 1.10-1.91). In landmark analyses of those alive at 90 days, there were no interactions between randomized testing and use of statins (&lt;jats:italic&gt;P&lt;/jats:italic&gt; value for interaction = .22), β-blockers (&lt;jats:italic&gt;P&lt;/jats:italic&gt; value for interaction = .76), or antiplatelet agents (&lt;jats:italic&gt;P&lt;/jats:italic&gt; value for interaction = .49).Conclusions and RelevanceIn long-term follow-up of the PROMISE randomized clinical trial, initial noninvasive te","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"82 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iodinated Adhesive Drapes for Repeat Cardiac Implantable Device Implantation","authors":"Alper Aydin, Mehrdad Golian, Andres Klein, Calum Redpath, Darryl R. Davis, F. Daniel Ramirez, Girish M. Nair, Martin S. Green, Mouhannad Sadek, Pablo B. Nery, Simon P. Hansom, Ghalib Al Hinai, Willy Weng, Nicolas Berbenetz, Michael J. Thibert, Yasmeen Salmeen, Evan Martow, Li Wei Tan, Ghaith Almidani, Abdullah Alshehri, Anas Alzahrani, Fahad Alharbi, Vicente Corrales-Medina, George A. Wells, David H. Birnie","doi":"10.1001/jamacardio.2025.2835","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2835","url":null,"abstract":"ImportanceOne potential pathophysiological mechanism for cardiac implantable electronic device (CIED) infections is pocket contamination during the implantation procedure. Preventing contamination at this stage may significantly reduce the risk of infections.ObjectiveTo determine whether the application of an intraoperative adhesive iodine-impregnated drape would reduce the rate of end-of-procedure pocket-swab positivity and subsequent CIED infections.Design, Setting, and ParticipantsThis was a prospective, double-armed, single-blinded, randomized clinical trial, conducted from November 2020 to May 2024. Patients, the staff performing the swabs, and the microbiologists were blinded to group assignments. This was a single-center study that included patients undergoing repeat procedures on the same device pocket. These patients were randomized in a 1:1 ratio to either the iodine-impregnated drape group or the control group.InterventionApplication of an iodine-impregnated drape at the beginning of the procedure.Main Outcomes and MeasuresThe primary end point was end-of-procedure pocket-swab culture positivity.ResultsA total of 418 patients were randomized (210 to the drape group and 208 to the no-drape group). The final analysis included 189 patients in the drape group and 195 patients in the no-drape group, with both groups well balanced in demographics. In the drape group, 143 participants were male (75.7%), and mean (SD) age was 73.9 (12.1) years; in the no-drape group, 140 were male (71.8%), and mean (SD) age was 73.2 (12.6) years. Pocket-swab culture positivity was found in 19 of 189 patients (10.1%) in the drape group compared with 40 of 195 patients (20.5%) in the no-drape group (relative risk reduction [RRR], 0.50; 95% CI, 0.24-0.75; <jats:italic>P</jats:italic> = .005). Adjudicated CIED infections occurred in 4 of 195 patients (1.9%) in the no-drape group vs 0 of 189 in the drape group (<jats:italic>P</jats:italic> = .02). CIED infections were observed in 2 of 59 patients (3.4%) with positive swabs and in 2 of 325 patients (0.6%) with negative swabs (odds ratio, 5.67; 95% CI, 0.78-41.04; <jats:italic>P</jats:italic> = .08).Conclusions and RelevanceIn this randomized clinical trial, the use of iodine-impregnated drapes during repeat CIED implantation resulted in reduction in swab culture positivity and 1-year CIED infection rates. This is a simple and cost-effective intervention to reduce CIED pocket contamination and subsequent infections.Trial RegistrationClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http://www.w3.org/1999/xlink\" ext-link-type=\"uri\" xlink:href=\"https://www.clinicaltrials.gov/study/NCT04591366\">NCT04591366</jats:ext-link>","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"18 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144910950","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Trimethylamine N-Oxide and Growth Rate of Abdominal Aortic Aneurysms and Surgical Risk","authors":"Scott J. Cameron, Xinmin S. Li, Tyler W. Benson, Kelsey A. Conrad, Zeneng Wang, Salma Fleifil, Lars Maegdefessel, Kevin Mani, Martin Björck, Alliefair Scalise, Michael Pham, Sharon Shim, Anders Wanhainen, Betemariam Sharew, Melissa Y. Tian, Yuping Wu, Aldons J. Lusis, Sean P. Lyden, W. H. Wilson Tang, A. Phillip Owens, Stanley L. Hazen","doi":"10.1001/jamacardio.2025.2698","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2698","url":null,"abstract":"ImportancePlasma levels of the gut microbiota–dependent metabolite trimethylamine <jats:italic>N</jats:italic>-oxide (TMAO) are associated with prevalent abdominal aortic aneurysms (AAA) in humans and fostering of AAA progression in animal models; therapeutic targeting of TMAO production blocks AAA progression and rupture in multiple mouse models. A blood biomarker that identifies individuals at risk for incident AAA development, accelerated AAA expansion, or recommendation for surgical AAA repair could be an asset for risk stratification.ObjectiveTo determine whether TMAO is associated with risk for AAA development, rapid AAA expansion, and risk for recommended surgical intervention.Design, Setting, and ParticipantsThis was a prospective cohort study using 2 independent clinical cohorts undergoing aorta imaging surveillance: a European cohort and a US cohort. Included in this study were patients undergoing serial imaging surveillance of the aorta and long-term outcome monitoring. Patients were recruited from single-center studies in Uppsala, Sweden, and Cleveland, Ohio. Study data were analyzed from October 2023 to May 2025.ExposuresPlasma TMAO concentrations measured by stable isotope dilution liquid chromatography with tandem mass spectrometry.Main Outcomes and MeasuresThe association of TMAO levels with AAA risk, fast-growing AAA (≥4.0 mm per year), and recommended surgical intervention (≥4.0 mm per year or ≥5.5 cm diameter).ResultsThe European cohort included 237 individuals (median [IQR] age, 65 [65-73] years; 211 male [89.0%]), and the US cohort included 658 individuals (median [IQR] age, 63 [57-70] years; 523 male [79.5%]). In the European cohort, elevated circulating TMAO was significantly associated with AAA risk independent of traditional risk factors and kidney function. Moreover, elevated TMAO predicted both greater risk for fast-growing AAA (adjusted odds ratio [aOR], 2.75; 95% CI, 1.20-6.79) and recommended surgical intervention (aOR, 2.67; 95% CI, 1.24-6.09). Similar patterns were observed in the US cohort and the combined European and US cohort, with heightened circulating TMAO corresponding with significantly increased adjusted risk for fast-growing AAA (US cohort: aOR, 2.71; 95% CI, 1.53-4.80; combined cohort: aOR, 2.30; 95% CI, 1.47-3.62) and recommended surgical intervention (US cohort: aOR, 2.73; 95% CI, 1.56-4.80; combined cohort: aOR, 2.41; 95% CI, 1.55-3.74). Addition of TMAO to base models containing traditional cardiovascular risk factors resulted in significant improvement in both risk estimation for fast-growing AAA and predicting recommended surgical intervention.Conclusion and RelevanceResults of this cohort study suggest that elevated circulating TMAO levels were associated with increased risk of AAA and identified patients at heightened risk for fast-growing AAA and recommended surgical intervention. TMAO may help identify individuals who may benefit from more frequent surveillance imaging and early surgical inter","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"23 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144901845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing Cascade Testing to Advance Health Equity in Cardiac Amyloidosis","authors":"Alexandra M.s Trevino, Sadiya S. Khan, Lisa M. Dellefave-Castillo, Laura J. Rasmussen-Torvik","doi":"10.1001/jamacardio.2025.2709","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2709","url":null,"abstract":"This Viewpoint assesses barriers to cascade testing of first-degree relatives of individuals with cardiac amyloidosis and considers opportunities to promote health equity in genomic testing.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"22 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Statin Eligibility According to Atherosclerotic Cardiovascular Disease Risk in the US","authors":"Sadiya S. Khan, Xiaoning Huang, Chiadi E. Ndumele, Roger S. Blumenthal, Michael J. Pencina, Allan D. Sniderman, Nilay S. Shah, John T. Wilkins, Donald M. Lloyd-Jones","doi":"10.1001/jamacardio.2025.2725","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2725","url":null,"abstract":"This cross-sectional study evaluates the implications of using the Predicting Risk of Cardiovascular Disease Events criteria to assess 10-year atherosclerotic cardiovascular disease risk estimates.","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"31 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salt Substitution and Recurrent Stroke and Death.","authors":"David A McCarron, Niels Graudal","doi":"10.1001/jamacardio.2025.2600","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2600","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":" ","pages":""},"PeriodicalIF":14.1,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Salt Substitution and Recurrent Stroke and Death-Reply.","authors":"Xiong Ding,Maoyi Tian,Lijing L Yan","doi":"10.1001/jamacardio.2025.2603","DOIUrl":"https://doi.org/10.1001/jamacardio.2025.2603","url":null,"abstract":"","PeriodicalId":14657,"journal":{"name":"JAMA cardiology","volume":"4 1","pages":""},"PeriodicalIF":24.0,"publicationDate":"2025-08-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144825006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}